Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.
about
Sustained-Release Naltrexone For Opioid DependenceThe effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.Management of relapse in naltrexone maintenance for heroin dependence.Advances in opioid antagonist treatment for opioid addiction.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.Rapid opiate detoxification and antagonist induction under general anaesthesia or intravenous sedation is humane, sometimes essential and should always be an option. Three illustrative case reports involving diabetes and epilepsy and a review of theImproved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy.Clinical safety of 1500 mg oral naltrexone overdose.Sustained-release naltrexone: novel treatment for opioid dependence.Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexoneDeficit of circulating stem--progenitor cells in opiate addiction: a pilot studyIllicit opioid intoxication: diagnosis and treatment.Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program.Evidenced-based treatment of opioid-dependent patients.Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?Addiction: the clinical interface.Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.Antagonist-agonist combinations as therapies for heroin addiction: back to the future?Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA-PEG-PLGA.Favorable mortality profile of naltrexone implants for opiate addiction.Emergency naloxone for heroin overdose: naloxone is not the only opioid antagonist.Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.Commentary on Krupitsky et al.(2013): Refuge from the streets--parked on methadone, or seeking shelter of a depot?Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.Treatment research in prison: Problems and solutions in a randomized trial
P2860
Q24243205-C8BD91D0-AD39-4D46-BE1C-9660985785F5Q30490602-6C39F3CE-D127-4419-B8C8-9F7A53B0810FQ33582025-2A03DEDA-A6E6-496B-81B0-070B7FA7CDB3Q34128519-95DA0417-A087-478C-8757-550F87CD7F05Q34262649-0431AA94-A459-4553-B26A-9809BABA9C6DQ34277168-C8B1F206-621F-4125-9C5A-1E5962191976Q34357213-753F0120-6A3C-40F9-B7E5-7BE42C090F74Q34371727-CFCBFFB0-A815-45E4-A8E6-6D5D8A970A72Q34525271-2BA36387-E26B-4A02-A467-85D73FA3CDC3Q34526419-11478D08-4FD1-4634-845B-925C8F657A78Q34660956-A77C5AAC-845E-470F-9D9E-A50D18A8F083Q35090939-3E443FB5-247B-4C88-BC8E-ABE0EAAC5187Q35540686-E391057D-8CA8-4613-B5D2-F4FBDBEF211CQ35619851-61174934-4FC9-4D4E-8F37-48ECC97D0E9EQ35943702-E2667C01-7E67-4A6D-BDF7-2ACC6210B4E0Q36138964-E007EB99-B8AD-4B78-A31E-47970495153EQ36300075-DE8C4A2B-2AF0-4770-B57D-760612D7D2C0Q36362007-984ED76C-CC7C-4C16-BB79-FD1007FA1AEDQ36398092-158E7643-5CB9-4889-8170-2C92E0885FCBQ36628470-CEDFF1BE-55F1-43BF-A736-2AB95B9911F9Q36664852-4A3F6FC4-625A-480D-8140-0C1646A7E555Q36741908-C4D5A851-BA1B-4D7C-8719-8BE2A00D57F1Q37873579-D22B50CB-1AB7-42BC-B806-B4D32A14F3CDQ39902056-AE7E9566-C5E6-4E82-94C9-E270AEF815B9Q41988316-29549207-65D9-47E8-8ACD-A9ABF86C3734Q43100374-18966B6A-051F-43DD-B2AD-55049843F17CQ43249025-2F7592AC-4726-45EB-AB59-123EAF1E9CCCQ45089599-337C778C-AC67-4DFC-AB42-1D35006E5363Q45333582-0D33DFDA-6B00-4D98-AC04-98B051943901Q52317035-5CE4361A-A497-4B9F-9B8A-1FE084B73F39Q58283771-354ABA94-844F-43F5-98C1-DF9CD6A95191
P2860
Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reducing hospital presentation ...... d release naltrexone implants.
@ast
Reducing hospital presentation ...... d release naltrexone implants.
@en
type
label
Reducing hospital presentation ...... d release naltrexone implants.
@ast
Reducing hospital presentation ...... d release naltrexone implants.
@en
prefLabel
Reducing hospital presentation ...... d release naltrexone implants.
@ast
Reducing hospital presentation ...... d release naltrexone implants.
@en
P2093
P2860
P1476
Reducing hospital presentation ...... d release naltrexone implants.
@en
P2093
Diane Arnold-Reed
Gary K Hulse
Ian G Jacobs
Maria A Sullivan
Sandra D Comer
P2860
P304
P356
10.1016/J.DRUGALCDEP.2005.02.009
P577
2005-09-01T00:00:00Z